Information Provided By: 
Fly News Breaks for August 4, 2017
TXMD
Aug 4, 2017 | 08:20 EDT
After TherapeuticsMD provided an update on the regulatory process for both TX-004HR and TX-001HR, Oppenheimer analyst Jay Olson says he believes the narrative between the company and the FDA has become "more collaborative." This suggests next week's potential update on TX-004HR could be favorable, Olson tells investors in a research note. The analyst keeps an Outperform rating on TherapeuticsMD with a $10 price target.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
